Summary
Cannot determine label alignment because the provided FDA label excerpts do not contain information supporting most claims (e.g., insulin/glucose effects, nausea/diarrhea, pancreatitis risk, cardiovascular outcomes, insulin sensitivity, satiety, once-weekly dosing). The only on-label content supplied relates to thyroid C-cell tumor risk and related contraindication/counseling, which is not addressed by the AI claims provided.
Category Scores
Accurate Statements
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Supported only insofar as the provided excerpts identify semaglutide as a GLP-1 receptor agonist (e.g., in the context of thyroid C-cell tumor warning and liraglutide comparison).
Ozempic is associated with nausea and vomiting, particularly when first starting treatment.
No support for nausea/vomiting is present in the supplied label excerpts.
Ozempic is associated with diarrhea.
No support for diarrhea is present in the supplied label excerpts.
Ozempic is associated with a potential increased risk of pancreatitis.
No support for pancreatitis is present in the supplied label excerpts.
Unsupported Statements
Ozempic works by stimulating the release of insulin.
No information about insulin release mechanism is included in the supplied label excerpts.
Ozempic works by slowing down the production of glucose in the liver.
No information about hepatic glucose production is included in the supplied label excerpts.
Ozempic can increase insulin sensitivity.
No information about insulin sensitivity is included in the supplied label excerpts.
Ozempic reduces glucose production in the liver.
No information about hepatic glucose production is included in the supplied label excerpts.
Ozempic can improve insulin sensitivity and reduce glucose production in individuals with type 2 diabetes.
No mechanism/outcomes for type 2 diabetes are included in the supplied label excerpts.
Ozempic can improve insulin sensitivity and reduce glucose production, making it an effective treatment option for individuals with type 2 diabetes.
No efficacy/indication text or dosing-to-efficacy statements are included in the supplied label excerpts.
Ozempic can have a positive impact on sugar tolerance in individuals with type 2 diabetes.
No information about sugar tolerance is included in the supplied label excerpts.
Ozempic can reduce hunger and increase feelings of fullness (satiety).
No information about hunger/satiety is included in the supplied label excerpts.
Ozempic may lead to dehydration and electrolyte imbalances due to diarrhea.
No information about dehydration/electrolyte imbalances or diarrhea complications is included in the supplied label excerpts.
A study found that semaglutide (Ozempic) significantly improved insulin sensitivity and reduced glucose production in individuals with type 2 diabetes.
No study details about insulin sensitivity or glucose production are included in the supplied label excerpts.
Ozempic reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes.
No cardiovascular outcomes information is included in the supplied label excerpts.
Ozempic is taken once a week.
No dosing frequency information is included in the supplied label excerpts.
Contradictions
Low
AI Statement
No direct contradictions were verifiable against the supplied label excerpts.
Label Reference
Important Omissions
Boxed warning and associated counseling/precautions about thyroid C-cell tumors (including that it is contraindicated in patients with personal/family history of MTC or MEN 2, and counsel patients about thyroid tumor symptoms).
Importance:
High
Contraindication regarding serious hypersensitivity reactions to semaglutide or excipients (including mention of anaphylaxis/angioedema).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The supplied label excerpts include a boxed warning and explicit contraindications related to thyroid C-cell tumors (MTC/MEN 2) and serious hypersensitivity. None of the AI claims address these safety-critical items, and many other claims are unsupported by the supplied excerpts. This creates a high risk of incomplete or misleading label-alignment assessment from the provided claim set.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Missing boxed warning/contraindication content (thyroid C-cell tumors; MTC/MEN 2) and most efficacy/dosing/mechanism/adverse event claims are unsupported by the provided label excerpts.
Suggested Improvement
Include label-supported boxed warning and contraindications from sections 4 and 5.1 (and counseling from section 17). Limit other mechanistic/clinical-effect and adverse-event statements to areas explicitly supported by the provided label text (or provide the relevant additional label sections for evaluation, including dosage/frequency and adverse reactions).